[Experimental studies in vitro on the alpha-fetoprotein-specific promoter mediated target gene therapy of hepatocellular carcinoma].
To investigate the alpha-fetoprotein (AFP)-specific promoter mediated target gene therapy of hepatocellular carcinoma in vitro. Retroviral vector (LX2.2CD) in which the cytosine deaminase (CD) gene was driven by the 2.2 kb recombinant human AFP TRS. After transfecting three human hepatoma cell lines and one non-hepatoma cell line with LX2.2 CD, anti-G418 clones integrated CD gene were selected, and inhibitory experiment of cell growth was performed. 5-fluorocytosine (5FC) could confer the chemosensitivity to transduced AFP-producing hepatoma cells (HuH-7 and huH-1/c1-2), but not to AFP-nonproducing hepatoma cells (HLE) or nonhepatoma cells (GLC). On the other hand, when transfecting the above four tumor cell lines with another retroviral vector pCD2 (CD gene was driven by 5'LTR internal promoter), no cell selection was found in 5FC-induced cell grow inhibition. Recombinant retrovival transfer of the CD gene under the control of the AFP TRS followed by 5FC may well be a promising trageted gene therapy for hepatoma.